TrialsgrambetaRCTs are beautiful

IPASS

2009

Iressa Pan-Asia Study

In 1,217 Asian, never/light-smoker patients with advanced lung adenocarcinoma, gefitinib improved progression-free survival in the EGFR-mutation-positive subgroup compared with carboplatin + paclitaxel.

Result

Efficacy: Progression-free survivalHR 0.74

Below 1 favours gefitinib, above 1 favours carboplatin + paclitaxel.

Also reported: EGFR-mutated: HR 0.48; EGFR wild-type: HR 2.85. Striking qualitative interaction.

Original publication
Subtopic
EGFR-mutant NSCLC
Design
Open-label RCT
Relevance
Practice-defining: a trial the field needs to know.
Source
Mok TS, et al. N Engl J Med. 2009;361(10):947-957.doi 10.1056/NEJMoa0810699

Discussion & critique

Foundational trial of precision oncology: mandated EGFR-mutation testing before first-line therapy in advanced NSCLC.